Applied Genetic Technologies (NASDAQ:AGTC) will provide a management update on its planned Phase 2/3 X-Linked Retinitis Pigmentosa (XLRP) clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5 on September 9, 2020.
The Company will also report financial results for Q4 and FY 2020 before the market opens on September 9.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.